322 related articles for article (PubMed ID: 17557337)
1. Clinical correlates of mitochondrial function in Huntington's disease muscle.
Turner C; Cooper JM; Schapira AH
Mov Disord; 2007 Sep; 22(12):1715-21. PubMed ID: 17557337
[TBL] [Abstract][Full Text] [Related]
2. Biochemical abnormalities and excitotoxicity in Huntington's disease brain.
Tabrizi SJ; Cleeter MW; Xuereb J; Taanman JW; Cooper JM; Schapira AH
Ann Neurol; 1999 Jan; 45(1):25-32. PubMed ID: 9894873
[TBL] [Abstract][Full Text] [Related]
3. Weight loss in Huntington disease increases with higher CAG repeat number.
Aziz NA; van der Burg JM; Landwehrmeyer GB; Brundin P; Stijnen T; ; Roos RA
Neurology; 2008 Nov; 71(19):1506-13. PubMed ID: 18981372
[TBL] [Abstract][Full Text] [Related]
4. Autopsy-proven Huntington's disease with 29 trinucleotide repeats.
Kenney C; Powell S; Jankovic J
Mov Disord; 2007 Jan; 22(1):127-30. PubMed ID: 17115386
[TBL] [Abstract][Full Text] [Related]
5. Mitochondrial-dependent apoptosis in Huntington's disease human cybrids.
Ferreira IL; Nascimento MV; Ribeiro M; Almeida S; Cardoso SM; Grazina M; Pratas J; Santos MJ; Januário C; Oliveira CR; Rego AC
Exp Neurol; 2010 Apr; 222(2):243-55. PubMed ID: 20079354
[TBL] [Abstract][Full Text] [Related]
6. Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington's disease.
Saft C; Zange J; Andrich J; Müller K; Lindenberg K; Landwehrmeyer B; Vorgerd M; Kraus PH; Przuntek H; Schöls L
Mov Disord; 2005 Jun; 20(6):674-9. PubMed ID: 15704211
[TBL] [Abstract][Full Text] [Related]
7. HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism.
Seong IS; Ivanova E; Lee JM; Choo YS; Fossale E; Anderson M; Gusella JF; Laramie JM; Myers RH; Lesort M; MacDonald ME
Hum Mol Genet; 2005 Oct; 14(19):2871-80. PubMed ID: 16115812
[TBL] [Abstract][Full Text] [Related]
8. Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy: correlation between the density of inclusions and IT15 CAG triplet repeat length.
Becher MW; Kotzuk JA; Sharp AH; Davies SW; Bates GP; Price DL; Ross CA
Neurobiol Dis; 1998 Apr; 4(6):387-97. PubMed ID: 9666478
[TBL] [Abstract][Full Text] [Related]
9. Aberrant connectivity of lateral prefrontal networks in presymptomatic Huntington's disease.
Wolf RC; Sambataro F; Vasic N; Schönfeldt-Lecuona C; Ecker D; Landwehrmeyer B
Exp Neurol; 2008 Sep; 213(1):137-44. PubMed ID: 18588876
[TBL] [Abstract][Full Text] [Related]
10. Deterioration of mitochondrial bioenergetics and ultrastructure impairment in skeletal muscle of a transgenic minipig model in the early stages of Huntington's disease.
Rodinova M; Krizova J; Stufkova H; Bohuslavova B; Askeland G; Dosoudilova Z; Juhas S; Juhasova J; Ellederova Z; Zeman J; Eide L; Motlik J; Hansikova H
Dis Model Mech; 2019 Jul; 12(7):. PubMed ID: 31278192
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS.
Killoran A; Biglan KM; Jankovic J; Eberly S; Kayson E; Oakes D; Young AB; Shoulson I
Neurology; 2013 May; 80(22):2022-7. PubMed ID: 23624566
[TBL] [Abstract][Full Text] [Related]
12. Huntington's disease and mitochondrial DNA deletions: event or regular mechanism for mutant huntingtin protein and CAG repeats expansion?!
Banoei MM; Houshmand M; Panahi MS; Shariati P; Rostami M; Manshadi MD; Majidizadeh T
Cell Mol Neurobiol; 2007 Nov; 27(7):867-75. PubMed ID: 17952586
[TBL] [Abstract][Full Text] [Related]
13. The neurology and natural history of patients with indeterminate CAG repeat length mutations of the Huntington disease gene.
Panegyres PK; Goh JG
J Neurol Sci; 2011 Feb; 301(1-2):14-20. PubMed ID: 21147489
[TBL] [Abstract][Full Text] [Related]
14. Relationship between CAG repeat length and brain volume in premanifest and early Huntington's disease.
Henley SM; Wild EJ; Hobbs NZ; Scahill RI; Ridgway GR; Macmanus DG; Barker RA; Fox NC; Tabrizi SJ
J Neurol; 2009 Feb; 256(2):203-12. PubMed ID: 19266143
[TBL] [Abstract][Full Text] [Related]
15. [Huntington disease. A review].
Bonilla E
Invest Clin; 2000 Jun; 41(2):117-41. PubMed ID: 10961047
[TBL] [Abstract][Full Text] [Related]
16. Genetics and neuropathology of Huntington's disease.
Reiner A; Dragatsis I; Dietrich P
Int Rev Neurobiol; 2011; 98():325-72. PubMed ID: 21907094
[TBL] [Abstract][Full Text] [Related]
17. Triplet repeat mutation length gains correlate with cell-type specific vulnerability in Huntington disease brain.
Shelbourne PF; Keller-McGandy C; Bi WL; Yoon SR; Dubeau L; Veitch NJ; Vonsattel JP; Wexler NS; ; Arnheim N; Augood SJ
Hum Mol Genet; 2007 May; 16(10):1133-42. PubMed ID: 17409200
[TBL] [Abstract][Full Text] [Related]
18. Clinical and genetic characteristics in patients with Huntington's disease from China.
Yang J; Chen K; Wei Q; Chen Y; Cao B; Burgunder JM; Shang HF
Neurol Res; 2016 Oct; 38(10):916-20. PubMed ID: 27483361
[TBL] [Abstract][Full Text] [Related]
19. Huntington's disease.
Roze E; Bonnet C; Betuing S; Caboche J
Adv Exp Med Biol; 2010; 685():45-63. PubMed ID: 20687494
[TBL] [Abstract][Full Text] [Related]
20. Juvenile Huntington's disease: does a dosage-effect pathogenic mechanism differ from the classical adult disease?
Squitieri F; Frati L; Ciarmiello A; Lastoria S; Quarrell O
Mech Ageing Dev; 2006 Feb; 127(2):208-12. PubMed ID: 16274727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
